Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer

• Published in: Journal of hepatology Vol. 78; no. 2; pp. 333 - 342
• Main Authors: Okawa, Yuki, Iwasaki, Yusuke, Johnson, Todd A., Ebata, Nobutaka, Inai, Chihiro, Endo, Mikiko, Maejima, Kazuhiro, Sasagawa, Shota, Fujita, Masashi, Matsuda, Koichi, Murakami, Yoshinori, Nakamura, Toru, Hirano, Satoshi, Momozawa, Yukihide, Nakagawa, Hidewaki
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2023
• Subjects: Biliary tract cancer; Biliary Tract Neoplasms - genetics; Genetic Predisposition to Disease; Germ-Line Mutation; germline pathogenic variant; hereditary cancer; Homologous Recombination; homologous recombination deficiency; Humans; Whole Genome Sequencing; BTC; hereditary cancer; HRD; Biliary tract cancer; homologous recombination deficiency; germline pathogenic variant
• ISSN: 0168-8278; 1600-0641
• DOI: 10.1016/j.jhep.2022.09.025

The heritability and actionability of variants in homologous recombination-related genes in biliary tract cancers (BTCs) are uncertain. Although associations between BTC and BRCA germline variants have been reported, homologous recombination deficiency has not been investigated in BTCs. We sequenced germline variants in 27 cancer-predisposing genes in 1,292 BTC cases and 37,583 controls without a personal nor family history of cancer. We compared pathogenic germline variant frequencies between cases and controls and documented the demographic and clinical characteristics of carriers. In addition, whole-genome sequencing of 45 BTC tissues was performed to evaluate homologous recombination deficiency status. Targeted sequencing identified 5,018 germline variants, which were classified into 317 pathogenic, 3,611 variants of uncertain significance, and 1,090 benign variants. Seventy-one BTC cases (5.5%) had at least one pathogenic variant among 27 cancer-predisposing genes. Pathogenic germline variants enriched in BTCs were present in BRCA1, BRCA2, APC, and MSH6 (p <0.00185). PALB2 variants were marginally associated with BTC (p = 0.01). APC variants were predominantly found in ampulla of Vater carcinomas. Whole-genome sequencing demonstrated that three BTCs with pathogenic germline variants in BRCA2 and PALB2, accompanied by loss of heterozygosity, displayed homologous recombination deficiency. Conversely, pathogenic germline variants without a second hit or variants of other homologous recombination-related genes such as ATM and BRIP1 showed homologous recombination-proficient phenotypes. In this study, we describe the heritability and actionability of variants in homologous recombination-related genes, which could be used to guide screening and therapeutic strategies for BTCs. We found that 5.5% of biliary tract cancers (BTCs) in a Japanese population possessed hereditary cancer-predisposing gene alterations, including in BRCA and genes associated with colorectal cancer. Two hits in homologous recombination-related genes were required to confer a homologous recombination-deficient phenotype. PARP inhibitors and DNA-damaging regimens may be effective strategies against BTCs exhibiting homologous recombination deficiency. Hence, in this study, genome-wide sequencing has revealed a potential new therapeutic strategy that could be applied to a subset of BTCs. [Display omitted] •Hereditary cancer-predisposing gene alterations were identified in 5.5% of BTCs.•Germline variants in BRCA1/2, APC, MSH6 and PALB2 contributed significantly to BTC.•BTCs with germline variants in BRCA2 and PALB2 accompanied by LOH showed an HRD phenotype.